Search

Facilities must be flexible enough to cope with multiple modalities, including cell and gene therapies.

What are the lessons we must learn from the COVID-19 pandemic?

Supply chain lessons have been learned since COVID-19, so why are we seeing so many drug shortages?

Cytiva is transforming in the wake of COVID-19 – but what lessons can the wider biopharma industry take forward?

Exploring the potential of vaccines for treatment equity.

Your roundup of the key scientific studies and industry announcements emerging from the pandemic.

How the thoughtful adoption of new technology can both problem-solve and future- proof critical processes in biomanufacturing

We asked the field’s greatest minds: “What improvements do we need to see in cell and gene supply chains?”

Mike Rea of IDEA Pharma speaks frankly on the mud fights, echo chambers, and risks at play in the virtual forums of social media in 2021.

Novasep, Sartorius has solutions to assist with emerging modalities, such as mRNA, pDNA and AAV, as well as mAbs and traditional vaccines. At the company’s annual general shareholders’ meeting in March 2022,